Q32 Bio (QTTB)
Advances bempikibart, an anti-IL-7Rα antibody, for alopecia areata.
$13.80
Pre-market+0.25 (+1.85%)
At close$13.55(−5.64%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.36
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.16−$0.90−$0.78−$0.60$3.65−$0.54−$0.44Pending
Estimate−$1.25−$1.23−$1.14−$1.39−$0.85−$0.52−$0.46−$0.36
Surprise+7.2%+26.8%+31.6%+56.8%+529.4%−3.8%+4.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported————$53.7M——Pending
Estimate————$53.7M—$750.0K—
Surprise————0.0%———
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.36 | — | — |
| Aug 2026 | −$0.46 | −$0.44 | +4.3% |
| May 2026 | −$0.52 | −$0.54 | −3.8% |
| Mar 2026 | −$0.85 | $3.65 | +529.4% |
| Nov 2025 | −$1.39 | −$0.60 | +56.8% |
The latest year is open to everyone — the 32 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.36 | — | — | — | — | — | — |
| Aug 5, 2026 | −$0.46 | −$0.44 | +4.3% | $750.0K | — | — | +2.0% |
| May 5, 2026 | −$0.52 | −$0.54 | −3.8% | — | — | — | +6.4% |
| Mar 10, 2026 | −$0.85 | $3.65 | +529.4% | $53.7M | $53.7M | 0.0% | +15.4% |
| Nov 13, 2025 | −$1.39 | −$0.60 | +56.8% | — | — | — | −2.3% |
The latest year is open to everyone — the 32 quarters behind it read with an account. Sign in | |||||||
| Aug 6, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 13, 2024 | |||||||
| Nov 14, 2023 | |||||||
| Jul 27, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Dec 30, 2022 | |||||||
| Sep 29, 2022 | |||||||
| Jun 29, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Dec 30, 2021 | |||||||
| Sep 29, 2021 | |||||||
| Jun 29, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||